Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical has established an Audit Committee under its board of directors to enhance corporate governance and ensure effective supervision over management. This move aims to improve decision-making efficiency and maintain a robust understanding of the company’s financial and business management. The committee will consist of three to five directors, primarily independent non-executive members, and will oversee both internal and external audits, reinforcing the company’s commitment to transparency and accountability.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating within the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, medical devices, and healthcare services, with a significant presence in both domestic and international markets.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
See more data about 2196 stock on TipRanks’ Stock Analysis page.